GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003052220 | Esophagus | HGIN | intracellular receptor signaling pathway | 62/2587 | 265/18723 | 1.63e-05 | 4.50e-04 | 62 |
GO:004854527 | Esophagus | HGIN | response to steroid hormone | 73/2587 | 339/18723 | 6.06e-05 | 1.40e-03 | 73 |
GO:007138320 | Esophagus | HGIN | cellular response to steroid hormone stimulus | 44/2587 | 204/18723 | 1.56e-03 | 1.79e-02 | 44 |
GO:00483844 | Esophagus | HGIN | retinoic acid receptor signaling pathway | 11/2587 | 31/18723 | 2.02e-03 | 2.12e-02 | 11 |
GO:004340118 | Esophagus | HGIN | steroid hormone mediated signaling pathway | 31/2587 | 136/18723 | 3.01e-03 | 2.88e-02 | 31 |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
GO:0071383110 | Esophagus | ESCC | cellular response to steroid hormone stimulus | 127/8552 | 204/18723 | 1.26e-06 | 1.55e-05 | 127 |
GO:004340119 | Esophagus | ESCC | steroid hormone mediated signaling pathway | 87/8552 | 136/18723 | 1.25e-05 | 1.15e-04 | 87 |
GO:000975516 | Esophagus | ESCC | hormone-mediated signaling pathway | 106/8552 | 190/18723 | 3.13e-03 | 1.30e-02 | 106 |
GO:004838412 | Esophagus | ESCC | retinoic acid receptor signaling pathway | 22/8552 | 31/18723 | 3.90e-03 | 1.58e-02 | 22 |
GO:00325261 | Esophagus | ESCC | response to retinoic acid | 63/8552 | 107/18723 | 4.05e-03 | 1.62e-02 | 63 |
GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
GO:004854522 | Liver | HCC | response to steroid hormone | 206/7958 | 339/18723 | 6.81e-12 | 2.92e-10 | 206 |
GO:007138322 | Liver | HCC | cellular response to steroid hormone stimulus | 128/7958 | 204/18723 | 3.92e-09 | 1.04e-07 | 128 |
GO:004340121 | Liver | HCC | steroid hormone mediated signaling pathway | 84/7958 | 136/18723 | 4.42e-06 | 5.62e-05 | 84 |
GO:000975521 | Liver | HCC | hormone-mediated signaling pathway | 106/7958 | 190/18723 | 1.45e-04 | 1.17e-03 | 106 |
GO:00483841 | Liver | HCC | retinoic acid receptor signaling pathway | 20/7958 | 31/18723 | 1.11e-02 | 4.09e-02 | 20 |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:003052218 | Oral cavity | OSCC | intracellular receptor signaling pathway | 149/7305 | 265/18723 | 8.69e-09 | 1.81e-07 | 149 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa0521620 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa05417114 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa05216110 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa052229 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0521628 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa052237 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa046599 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0492816 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0522216 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0521638 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0465914 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0492817 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RXRB | SNV | Missense_Mutation | novel | c.1201N>A | p.Leu401Ile | p.L401I | P28702 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RXRB | SNV | Missense_Mutation | novel | c.1324N>A | p.Leu442Ile | p.L442I | P28702 | protein_coding | deleterious(0.03) | probably_damaging(0.978) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRB | SNV | Missense_Mutation | rs768018496 | c.821N>T | p.Ala274Val | p.A274V | P28702 | protein_coding | deleterious(0.01) | benign(0.012) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRB | insertion | In_Frame_Ins | novel | c.1243_1244insACCCTCAACCTGGAAATCTCCCAACTGGCCGAGGAAAAA | p.Ala415delinsAspProGlnProGlyAsnLeuProThrGlyArgGlyLysThr | p.A415delinsDPQPGNLPTGRGKT | P28702 | protein_coding | | | TCGA-A5-A0GA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
RXRB | insertion | Frame_Shift_Ins | novel | c.1306dupA | p.Arg436LysfsTer17 | p.R436Kfs*17 | P28702 | protein_coding | | | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRB | SNV | Missense_Mutation | novel | c.874N>T | p.Ala292Ser | p.A292S | P28702 | protein_coding | tolerated(0.56) | benign(0.013) | TCGA-2Y-A9GZ-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD |
RXRB | SNV | Missense_Mutation | | c.671N>T | p.Gly224Val | p.G224V | P28702 | protein_coding | deleterious(0) | possibly_damaging(0.773) | TCGA-CC-A123-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
RXRB | SNV | Missense_Mutation | novel | c.785N>G | p.Tyr262Cys | p.Y262C | P28702 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DD-AAEE-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
RXRB | insertion | Frame_Shift_Ins | novel | c.971_972insG | p.Thr325AsnfsTer4 | p.T325Nfs*4 | P28702 | protein_coding | | | TCGA-WQ-A9G7-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RXRB | SNV | Missense_Mutation | | c.881N>C | p.Gly294Ala | p.G294A | P28702 | protein_coding | tolerated(0.1) | benign(0.01) | TCGA-78-7539-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | TRETINOIN | TRETINOIN | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | CHEMBL1131 | ACITRETIN | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | antagonist | 135651303 | | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | modulator | CHEMBL146506 | MOFAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | TAZAROTENE | TAZAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | antagonist | 135650518 | | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135650520 | BEXAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | ALITRETIONINE | | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | CHEMBL1023 | BEXAROTENE | |
6257 | RXRB | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | BEXAROTENE | BEXAROTENE | |